Patterns of HCV-RNA and HCV core antigen in the early monitoring of standard treatment for chronic hepatitis C

Loggi, Elisabetta; Cursaro, Carmela; Scuteri, A.; Grandini, Elena; Panno, Arianna Martello; Galli, S.; Furlini, G.; Bernardi, Mauro; Galli, Claudio; Andreone, Pietro

doi:10.1016/j.jcv.2012.11.012

Cited by 18 publications

(22 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The kinetics of HCVAg at an early phase of treatment were similar to that of HCV-RNA with 3 slopes (day1, day 6, week 4). We confirmed an overall excellent correlation for HCVAg levels with HCV-RNA [12,[19][20][21]. This correlation resulted weaker at day T4 and later time points because of a faster draw-up of HCVAg under limit detection (<3 fmol/L).…”

Section: Discussionsupporting

confidence: 71%

See 1 more Smart Citation

The clinical significance of HCV core antigen detection during Telaprevir/Peg-Interferon/Ribavirin therapy in patients with HCV 1 genotype infection

Garbuglia

Lionetti

Lapa

et al. 2015

Journal of Clinical Virology

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 71%

“…This assay (Architect HCV core Antigen Test) has a sensitivity of 0.06 pg/mL or 3 fmol/L, corresponding to roughly 700-3000 IU/mL HCV-RNA according to the HCV genotype. This assay has been considered a useful parameter to monitor SOC therapy [12,13] and the employ been envisioned also for treatment with DAAs [14].…”

Section: Introductionmentioning

confidence: 99%

The clinical significance of HCV core antigen detection during Telaprevir/Peg-Interferon/Ribavirin therapy in patients with HCV 1 genotype infection

Garbuglia

Lionetti

Lapa

et al. 2015

Journal of Clinical Virology

View full text Add to dashboard Cite

“…While the complete mechanisms of inhibition of viral replication and of the production of viral antigens in patients undergoing treatment for chronic hepatitis C are still unclear, testing for HCVAg during either conventional or DAA-based treatment, as recently suggested [26,27], will bring only a marginal additional cost and may enable to identify some cases that will benefit from a closer monitoring of HCV-RNA levels in order to anticipate viral rebound.…”

Section: Discussionmentioning

confidence: 99%

HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

Garbuglia

Monachetti

Galli³

et al. 2014

BMC Infect Dis

Self Cite

View full text Add to dashboard Cite

BackgroundA good correlation between HCV core antigen (HCVAg) and different HCV-RNA assays has been described, but little data are available in HCV/HIV co-infection. We aimed to evaluate HCVAg in comparison with HCV-RNA and to determine their kinetics during antiviral treatment in selected HCV/HIV co-infected patients.Methods355 samples from 286 HCV/HIV co-infected subjects for whom HCV-RNA (Abbott RealTime) was requested were analysed also for HCVAg (Abbott ARCHITECT) in order to evaluate the correlation between the two parameters both in patients treated or untreated for chronic hepatitis C and according to different HCV genotypes. The differences between percentages were evaluated by chi square or Fisher’s exact test, while mean and median values were compared by Student’s t test or the Mann–Whitney test, respectively. All differences were considered significant for a p value <0.05.ResultsHCVAg was detectable on 288/315 sera (91.4%) positive for HCV-RNA and in 5 out of40 (12.5%) sera with undetectable HCV-RNA for a total concordance of 90.1%. The correlation was fair both in untreated (r = 0.742) and in treated (r = 0.881) patients and stronger for genotypes 1 and 4 than for genotype 3. Both HCV-RNA and HCVAg levels were significantly higher (p = 0.028 and p = 0.0098, respectively) in patients infected by genotype 1 than by genotype 3. The mean ratio of Log values between HCV-RNA (IU/mL) and HCVAg (fmol/liter) was 2.27 ± 1.09 in untreated and 2.20 ± 0.82 in treated patients (p = n.s.),consistent with a sensitivity of HCVAg corresponding to about 1,000 IU/mL of HCV-RNA, and ranged from 2.21 to 2.32 among HCV genotypes with no significant differences; five samples (1.4%; 2 genotype 1a or 1c, 3 genotype 3a) showed highly divergent values. The analysis of 18 monitoring profiles from patients treated with PEG-IFN and Ribavirin showed similar trends, except in one case in which relapse could be predicted by HCVAg and not by HCV-RNA.ConclusionThese results suggest that HCVAg represents an adequate tool for determining an ongoing HCV infection also in HIV co-infected patients, with lower costs and faster turnaround time than HCV-RNA.

show abstract

“…These assays have a broad dynamic range from 12 to 7,700,000 IU/ml, and a systematic review showed analytical sensitivity as low as 5 IU/ml for qualitative HCV RNA by NAT. Although either assay was recommended, the sensitivity and lower cost of qualitative assays for HCV RNA makes them preferable as a test of cure at 12 weeks or, conversely, presence of virus as an indication of ongoing HCV infection [163][164][165][166][167].…”

Section: Recommendations For Monitoring Of Treatment Response and Ratmentioning

confidence: 99%

“…However, the data on HCVcAg in treatment monitoring and assessment of test of cure (SVR) was considered to be too limited to yet recommend its use as a substitute for HCV RNA. The accuracy of two HCVcAg assays for treatment monitoring compared to NAT was assessed by descriptive analysis of five studies [165,[167][168][169][170].…”

Section: Recommendations For Monitoring Of Treatment Response and Ratmentioning

confidence: 99%

Who to test and how to test for chronic hepatitis C infection – 2016 WHO testing guidance for low- and middle-income countries

Easterbrook

2016

Journal of Hepatology

111

View full text Add to dashboard Cite

Patterns of HCV-RNA and HCV core antigen in the early monitoring of standard treatment for chronic hepatitis C

Cited by 18 publications

References 30 publications

The clinical significance of HCV core antigen detection during Telaprevir/Peg-Interferon/Ribavirin therapy in patients with HCV 1 genotype infection

The clinical significance of HCV core antigen detection during Telaprevir/Peg-Interferon/Ribavirin therapy in patients with HCV 1 genotype infection

HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

Who to test and how to test for chronic hepatitis C infection – 2016 WHO testing guidance for low- and middle-income countries

Contact Info

Product

Resources

About